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Edited by Peter BrzezinskiAbstract The properties of the heme, ﬂavin mononucleotide
(FMN) and FeS domains of P450 RhF, from Rhodococcus sp.
NCIMB 9784, expressed separately and in combination are ana-
lysed. The nucleotide preference, imidazole binding and reduc-
tion potentials of the heme and FMN domains are unaltered
by their separation. The intact enzyme is monomeric and the ﬂa-
vin is conﬁrmed to be FMN. The two one-electron reduction
potentials of the FMN are 240 and 270 mV. The spectro-
scopic and thermodynamic properties of the FeS domain, masked
in the intact enzyme, are revealed for the ﬁrst time, conﬁrming it
as a 2Fe–2S ferredoxin with a reduction potential of 214 mV.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The cytochrome P450 enzymes catalyse the two-electron
activation of molecular oxygen, with regio- and stereo-speciﬁc
insertion of one atom of oxygen into the substrate and reduc-
tion of the other to water [1].
RHþ 2e þO2 þ 2Hþ ! ROHþH2O ð1Þ
The nature of the redox partners, which supply reducing
equivalents, permits the P450s to be divided into two broad
classes. Class I P450s are three component systems typically
found in eukaryotic mitochondrial membranes and in prokary-
otes. In this class, an nicotinamide adenine dinucleotide (phos-
phate) (NAD(P)H)-binding ﬂavoprotein reductase supplies
electrons to the heme-containing monooxygenase via a small
ferredoxin. Class II enzymes are two component systems,
which utilise a membrane-associated diﬂavin reductase, con-
taining both ﬂavin mononucleotide (FMN) and ﬂavin adenineAbbreviations: NAD(P)H, nicotinamide adenine dinucleotide (phos-
phate), reduced form; FAD, ﬂavin adenine dinucleotide; FMN, ﬂavin
mononucleotide; LB, Luria–Bertani medium; IPTG, isopropyl b-D-1-
thiogalactopyranoside; ALA, 5-amino-4-oxo-pentanoic acid; PMSF,
phenylmethylsulfonyl ﬂuoride; PPM, parts per million; HPLC–MS,
high performance liquid chromatography–mass spectrometry; OT-
TLE, optically transparent thin layer electrochemistry; SHE, standard
hydrogen electrode
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to the monooxygenase. They are almost exclusively associated
with the eukaryotic endoplasmic reticulum, where they under-
take a wide variety of metabolic and detoxiﬁcation reactions.
One well-known exception is P450 BM3 (CYP102A) from
Bacillus megaterium, which comprises a heme-containing
monooxygenase domain fused to a diﬂavin reductase in a sin-
gle catalytically self-suﬃcient enzyme [2,3]. As such, it may be
likened to a fused class II enzyme. Several homologues from
diverse sources have been found by sequence analysis. For
example, two BM3 homologues (CYP102A2 and CYP102A3)
have been identiﬁed in Bacillus subtilis [4], with further exam-
ples from Bacillus anthracis, Bacillus cereus, Ralstonia metalli-
durans [5], Actinosynnema pretiosum [6], Fusarium oxysporum
[7] and Fusarium verticillioides [8].
Recently, several other P450s have emerged that have
primary structural organisations which do not fall into this gen-
eral classiﬁcation. For example, a novel P450 (MCCYP51FX)
involved in sterol biosynthesis, which is composed of a P450
heme-monooxygenase domain fused at the C-terminus to a
3Fe–4S type ferredoxin, has been identiﬁed in Methylococcus
capsulatus [9]. A second interesting example of a fused
cytochrome P450 system has been cloned from Rhodococcus
rhodochrous strain 11Y. This gene encodes a P450 heme-
monooxygenase domain fused to an N-terminal ﬂavodoxin-like
domain [10].
We recently reported the cloning and preliminary character-
isation of a novel P450, termed P450 RhF (CYP116B2) [11,12],
from Rhodococcus sp. NCIMB 9784. Analysis of the deduced
polypeptide revealed a heme-monooxygenase domain fused
to an FMN and iron–sulfur cluster-containing reductase, strik-
ingly similar to the phthalate dioxygenase reductase family
(Fig. 1). Analysis of the sequence showed the heme-monooxy-
genase domain to have a high degree of sequence identity
(55%) to the thiocarbamate-inducible P450 from Rhodococcus
erythropolis NI86/21 (ThcB), a class I enzyme (CYP116) [13].
Further examples of this type of fused P450 have since been
found in three pathogenic Burkholdaria species [5], R. metalli-
durans [5], Ralstonia eutropha JMP134. 1 and Gibberella zeae
PH-1. 2 To date the natural function of P450 RhF and its
homologues have not been determined.
In this paper, we further probe the function of this novel
fused P450 by analysing the properties of its three domains
(heme, FMN and FeS) individually and in combination.1 NCBI Accession # ZP_00170172.
2 NCBI Accession # EAA70206.
ation of European Biochemical Societies.
Fig. 1. Diagrammatic representation of the domain organisation of
P450 RhF based on sequence analysis. The segment of P450 RhF
sequence spanning the heme–ligand pocket is shown [11]. Truncated
versions of P450 RhF comprising individual domains and didomains
are illustrated below. In: intact P450 RhF; HF: heme–FMN didomain;
HD: heme domain; FF: FMN–FeS didomain; FD: FMN domain; FS:
FeS domain.
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2.1. Construction of expression vectors
Truncated versions of the gene, encoding individual domains and
domain combinations, were generated by PCR using the full-length
gene as template. The primer pairs used for the ampliﬁcation reactions
are given in Table 1. Each forward primer was designed to incorporate
an NdeI restriction site for cloning into pET14b. Each reverse primer
included a BclI restriction site after the natural or engineered stop co-
don. The PCR conditions were similar to those described previously
[12], except the extension at 72 C was varied from 45 s to 2 min,
depending on the size of ampliﬁed product.
The ampliﬁed products were digested with NdeI and BclI and cloned
into the NdeI/BamHI restriction sites of pET14b to give the ﬁnal
expression constructs. The insert DNA was sequenced to ensure no
mistakes had been introduced during the ampliﬁcation reaction.
2.2. Heterologous expression studies
Initially, Escherichia coli BL21(DE3) was used as the host strain for
the expression studies. However, improved expression of the heme–
FMN, heme and FeS domains was observed using E. coli BL21(DE3)-
pLysS as host. Starter cultures (150 ml LB medium plus appropriate
antibiotics) were grown at 37 C from single colonies to an optical den-
sity (OD600) of 0.5.
Large-scale cultures (10 l LB medium, supplemented with 0.1 lM
FeCl3 and appropriate antibiotics) of intact P450 RhF, FMN–FeS
and FeS domain were grown in a 15 l fermentor (Bioﬂo 4500, New
Brunswick Scientiﬁc, Edison, NJ, USA) at 30 C using a 50 ml inocu-
lum. Cultures were grown at 37 C to OD600 = 0.5. Heterologous gene
expression was induced by the addition of isopropyl b-D-1-thiogalacto-
pyranoside (IPTG) to 1 mM and the culture maintained for 3 h beforeTable 1
PCR primers used to amplify DNA encoding individual domains or didoma
Construct Forward primer (50–3 0)
Heme (1–444) CGGTGTCCATATGAGTGCATCAGTTC
Heme + FMN (1–675) CGGTGTCCATATGAGTGCATCAGTTC
FMN (445–677) CGGTGTCATATGCTGCACCGGCATCA
FMN + FeS (445–773) CGGTGTCATATGCTGCACCGGCATCA
FeS (684–773) CGGTGTCCATATGGAGCACGCCTTCG
The numbers in parentheses refer to the amino acid sequence of the protein p
an N-terminal His tag (6· His). The NdeI (forward primer) and BclI (reverse
highlighted in bold.harvesting. Where indicated, the culture was supplemented with the
heme precursor 5-amino-4-oxo-pentanoic acid (ALA, 0.25 mM) at
induction.
Improved expression was observed for recombinant strains harbor-
ing the heme–FMN, heme and FMN constructs when grown in shake-
ﬂasks. Therefore, large-scale cultures of the heme–FMN didomain,
heme domain and FMN domain were grown in 10 · 1.0 l baﬄed
shake-ﬂasks, each containing 500 ml LB medium and appropriate anti-
biotics. Cultures were grown to OD600 = 0.5 at 37 C and 180 rpm.
After addition of IPTG to 1.05 mM (FMN domain) or 2 lM (heme–
FMN and heme domains), the temperature was decreased to 30 C
and growth was continued for 12 h before harvesting.2.3. Puriﬁcation of domains
Since all the expression constructs encoded an N-terminal polyhisti-
dine tag, recombinant protein puriﬁcation was performed as described
previously for intact P450 RhF [12].2.4. Identiﬁcation of the ﬂavin component of P450 RhF
A 100 ll aliquot of puriﬁed FMN domain (150 lM) was boiled in
the dark for 5 min. After cooling, the denatured protein was removed
by centrifugation (13000 · g, 5 min, 4 C). The liberated ﬂavin was
analysed by high performance liquid chromatography–mass spectrom-
etry (HPLC–MS). Chromatography was performed on a Water Alli-
ance 2790 HPLC at 0.2 ml/min on a 2 · 250 mm, 5 lm Phenomenex
C-18(2) Luna column equilibrated with 5 mM ammonium acetate,
pH 7.2, 15% (v/v) methanol. A 20 min linear gradient from 15% to
90% (v/v) methanol in 5 mM ammonium acetate, pH 7.2, was carried
out. The puriﬁed ﬂavin (elution time 18.2 min) was analysed by elec-
trospray mass spectrometry in negative ionisation mode using a Micro-
mass Platform II MS.2.5. Heme and FMN analysis and ICP-OES
Heme content was estimated by means of the pyridine hemochromo-
gen method [14]. Flavin content was estimated by the method of
Macheroux [15]. Iron and sulfur contents were determined by induc-
tively coupled plasma-optical emission spectroscopy (ICP-OES) using
a Thermo Jarrell Ash IRIS spectrometer. Calibration standards were
diluted from 1000 ppm calibration standard solutions of each element
(Fisher Scientiﬁc, Loughborough, UK). All determinations were made
in triplicate.2.6. Iron–sulfur centre reloading
Reloading of the FeS centre of intact P450 RhF and the FMN–FeS
construct followed the method of Mulliez et al. [16].
2.7. Analytical ultracentrifugation
Puriﬁed P450 RhF (0.53 or 1.06 mg/ml) in 50 mM Tris/HCl, pH 7.8,
200 mM NaCl, 10% (v/v) glycerol was analysed by analytical ultracen-
trifugation. Samples (0.38 ml) were centrifuged in 1.2 cm path length 2-
sector aluminium centrepiece cells with sapphire windows, in a 4-place
An-60 Ti analytical rotor running in an Optima XL-I analytical ultra-
centrifuge (Beckman Instruments, Palo Alto, CA, USA) at 30000 rpm
and 20 C for 20 h. Changes in solute concentration were detected by
absorbance scans at 418 nm. Results were analysed by whole-bound-
ary analysis using the program Sedﬁt (version 8) [17] and by g(s\) anal-
ysis using the program DCDT+ (version 1.13) [18].ins of P450 RhF
Reverse primer (50–3 0)
CG CCGGTGTGATCAAGCAGGATCGGTGCGCTC
CG AGGTTGATCACGAGGTGAAGTGCTCG
A AGGTTGATCATCAGAGGGACGAGGTGAAGT
A AGGTTGATCATTCAGAGTCGCAGGGCCAGCC
ACCT AGGTTGATCATTCAGAGTCGCAGGGCCAGCC
roduct in relation to P450 RhF. The recombinant protein also included
primer) restriction recognition sites used in the cloning procedure are
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Imidazole was titrated into P450 RhF (5 lM protein in storage
buﬀer) by mixing with appropriate volumes of an identical solution
of P450 RhF treated with 2 mM imidazole. UV–vis spectra were re-
corded after each addition. After correction of the spectra for baseline
drift, diﬀerence spectra were calculated, and the absorbance changes at
435 vs. 414 nm for each were plotted against imidazole concentration.
Binding curves were ﬁtted to the data using Origin 7.0 software (Mic-
rocal, Northampton, MA, USA). Measurements were carried out in
triplicate.2.9. Pre-steady-state kinetics
Pre-steady-state measurements of the reduction of P450 RhF by
either NADPH or NADH were performed as described previously
[12].2.10. Optically transparent thin layer electrochemical (OTTLE)
potentiometry
Spectroelectrochemical analysis of P450 RhF was conducted as de-
scribed previously [12]. Potentiometry of the FeS domain was under-
taken in storage buﬀer with the additional mediator phenazine
ethosulfate (20 lM).Fig. 2. UV/visible spectra of puriﬁed P450 RhF domains. (A) Heme–
FMN didomain before (solid line) and after (dot–dash line) reduction
and CO-treatment, showing typical P450 spectrum. (B) Heme domain
before (solid line) and after (dot–dash line) reduction and CO-
treatment. (C) 2Fe–2S cluster reloaded FMN–FeS didomain (solid
line) and FMN domain (dot–dash line) at equivalent FMN concen-
trations. (D) FeS domain (solid line). Subtraction of the FMN
spectrum from the FMN–FeS spectrum in (C) is shown in inset.2.11. EPR spectroscopy
EPR spectra were recorded on an X-band ER-200D spectrometer
(Bruker Spectrospin, Coventry, UK) ﬁtted with a liquid helium ﬂow-
cryostat (ESR-9, Oxford Instruments, Oxford, UK). Spectra were re-
corded at 9.668 GHz, 10 K, 2.01 mWmicrowave power andmodulation
amplitude of 1 mT.3. Results and discussion
We have previously reported the cloning of a novel P450
with a fused phthalate dioxygenase-type (FMN, FeS) reduc-
tase, its heterologous expression in E. coli and its partial char-
acterisation [11,12]. This work extends the characterisation to
the individual domains of the enzyme, allowing their proper-
ties in isolation to be observed. This is of particular interest
in the case of the FeS domain, as the absence of interfering
heme and FMN groups allowed the spectroscopic and thermo-
dynamic properties of the FeS cluster, masked in the intact en-
zyme, to be probed for the ﬁrst time.
Intact P450 RhF, its individual domains and combinations
thereof, were routinely expressed to high yield in E. coli
BL21(DE3) cells. Minor modiﬁcations to the general expres-
sion protocol were introduced to maximise the yield of each re-
combinant protein. For example, the heme domain could be
expressed in good yield using a high concentration of IPTG
(1.05 mM), but under these conditions, little of the recombi-
nant protein contained heme (data not shown). Induction with
a much lower concentration of IPTG (2 lM) coupled with low
basal expression (use of E. coli BL21(DE3) pLysS) resulted in
much better incorporation of heme into the protein.
All recombinant proteins gave UV/vis spectra expected for
their prosthetic group content (Fig. 2), although the spectrum
from the FeS cluster was masked by the more intense FMN
and heme absorbances. However, it was possible to obtain a
spectrum for the FeS cluster in the presence of the FMN do-
main by subtraction of the spectrum of the FMN domain from
that of the FMN–FeS didomain. In these experiments, the
FMN–FeS didomain was reloaded with FeS cluster and
matched in concentration to the FMN domain by FMN con-
tent. The spectrum (Fig. 2D, inset) was very similar to that ob-
tained for the isolated FeS domain (Fig. 2D).It was noted that the intact P450 RhF displayed a lower
absorbance at 418 nm than expected on the basis of the pre-
dicted 1:1 ratio of heme to FMN. For this reason, the pros-
thetic group content of each construct was investigated more
closely. The heme, FMN, iron and sulfur content of single
samples of each recombinant protein was determined. Since
the sequence of each construct was known, the sulfur content
enabled a protein concentration to be accurately estimated for
each. However, the loading of the 2Fe–2S cluster then becomes
important, as the cluster introduces two inorganic sulfur
atoms. For proteins containing the 2Fe–2S cluster, we esti-
mated the protein concentration twice: assuming the cluster
to be absent (sulfur from protein sequence only) or fully
loaded (two additional sulfurs). These estimates therefore rep-
resent the upper and lower limits of prosthetic group loading.
Prosthetic group content varied from 14% to 48% (heme),
27% to 100% (FMN) and 4% to 36% (2Fe–2S). Problems with
heterologous expression of P450s, including low content of
prosthetic groups, have been reported before [19]. This is prob-
ably the result of recombinant protein expression outstripping
the supply and insertion of the prosthetic groups. The adop-
tion of growth conditions to alleviate this by supplementation
of the growth medium with the heme precursor ALA and ferric
iron at induction signiﬁcantly improved the levels of heme
incorporation.
The FeS cluster could be reloaded with iron and inorganic
sulfur, as observed in other ferredoxins and similar proteins
[16]. Reloading by anaerobic incubation of dithiothreitol-trea-
ted protein with ferrous iron and inorganic sulﬁde improved
the loading of the cluster in both intact P450 RhF and the
FMN–FeS didomain, to approximately 60–70% and 90%,
respectively. Our previous analysis of the deduced amino acid
sequence of P450 RhF identiﬁed four highly conserved cysteine
Fig. 4. Representative potentiometric titrations of P450 RhF domain
constructs. (A) Heme domain: Variation of absorbance with applied
potential associated with heme (418 nm), ﬁtted to a one electron
Nernst equation. (B) FMN–FeS construct: Variation of absorbance
with applied potential associated with FMN (462 nm, open circles) and
with the neutral blue FMN semiquinone (600 nm, open-dot circles),
ﬁtted simultaneously to two one-electron Nernst equations. (C) FeS
domain: Variation of absorbance with applied potential associated
with the 2Fe–2S cluster (420 nm), ﬁtted to a one-electron Nernst
equation. All ﬁtting used Origin 7.0 software (Microcal). (D) UV/vis
absorption spectrum obtained during the titration of the FeS domain
shown in (C). Thick lines indicate fully oxidised and fully reduced
spectra.
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polypeptide that constitute a 2Fe–2S ferredoxin-like redox cen-
tre [11]. Indeed, a portion of the primary amino acid sequence
(722CEEGLCGSC) corresponds to the PROSITE consensus
motif (Cxx[GA]xC[GAST]xC) for a [2Fe–2S] ferredoxin.
EPR spectroscopy of the reloaded FMN–FeS didomain gave
a spectrum typical of a 2Fe–2S ferredoxin, with g-values of
2.059, 1.969 and 1.880 (Fig. 3). These values are comparable
with those for the phthalate dioxygenase reductase (2.041,
1.949, 1.900) [20]. Furthermore, the EPR data gave no evi-
dence of non-speciﬁc FeS species upon reloading.
Our original sequence analysis of P450 RhF predicted that
the ﬂavin prosthetic group was FMN rather than FAD [11].
To test this experimentally, the ﬂavin prosthetic group was re-
leased from the puriﬁed FMN domain by heat denaturation
and then analysed by HPLC–MS. The liberated ﬂavin had
an identical retention time to an FMN standard on the HPLC
column and its mass, determined by electrospray mass spec-
trometry, was that expected for FMN (454.9 Da).
Sedimentation velocity analysis of intact P450 RhF gave an
estimated molecular mass of between 84 and 87 kDa. These
values correspond to the predicted mass of a monomer
(85 kDa). The monomeric nature of the intact protein and
the truncated forms of P450 RhF was also veriﬁed by analyt-
ical gel ﬁltration chromatography (data not shown).
Potentiometric analysis of the puriﬁed recombinant proteins
suggests that the separation of the domains of P450 RhF does
not lead to major changes in the thermodynamic properties of
their cofactors (Fig. 4 and Table 2). The heme reduction poten-
tial changes by only about +40 mV upon removal of the reduc-
tase portion of the protein. This magnitude of change is easily
ascribed to minor structural perturbations of the heme domain
and to the increased solvent exposure of the heme.
Binding of imidazole to the heme was similarly unaﬀected by
the separation of the domains of P450 RhF (Kd imidazole:
0.86, 0.67 and 0.46 mM for intact P450 RhF, heme–FMN
didomain and heme domain, respectively). The Kd values for
imidazole measured in this work are also very similar to the
Ki values obtained previously for imidazole-based inhibitors
[12].
Titration of the FMN group was monitored at two wave-
lengths, the data being ﬁtted simultaneously. This permitted
the two one-electron reduction potentials, oxidised to semiqui-
none (ox/sq) and semiquinone to hydroquinone (sq/hq), to beFig. 3. EPR spectrum of the FMN–FeS didomain. Data were
recorded at X-band (9.668 GHz), at a temperature of 10 K, with
2.01 mW microwave power and modulation amplitude of 1 mT.estimated. However, owing to the low absorbance intensity of
the blue neutral semiquinone at approximately 600 nm, the
errors in this estimation are signiﬁcant.
The potential of the 2Fe–2S cluster could not be determined
in the presence of the other domains since the spectral changes
accompanying its reduction are masked by the other prosthetic
groups. A small perturbation in the redox curve for the FMN–
FeS didomain at around 150 mV may be due to the 2Fe–2S
cluster, but this is of too low a magnitude for any sensible anal-
ysis. However, when isolated in the FeS domain, it proved
straightforward to titrate, giving a midpoint potential of
214 mV (Table 2). Since the 2Fe–2S cluster potential was
determined in the isolated domain, it is possible that it does
not exactly reﬂect the potential in the intact enzyme. However,
the value determined is within 40 mV of that for the 2Fe–2S
cluster of phthalate dioxygenase reductase [20,21] and is
appropriate, both in terms of known 2Fe–2S cluster potentials
[22] and of the suggested position of this centre in the electron
transfer pathway of this enzyme.
The potentials obtained for the reductase portion of the
P450 RhF may be compared with those published for the phth-
alate dioxygenase reductase from Burkholdaria cepacia [20,21].
This protein has 34% sequence identity with the reductase por-
tion of P450 RhF. In the phthalate dioxygenase reductase, the
FMN reduction potentials are 174 mV (ox/sq) and 287 mV
(sq/hq) with the 2Fe–2S reduction being 174 mV. The FMN
Table 2
Reduction potentials of the redox active centres of the domains of P450 RhF
Em heme (mV) Em FMN (mV) Em FeS (mV)
Oxﬁ Sq Sqﬁ Hq
Intact P450 [12] 423 ± 10 243 ± 15 (2e reduction) N/d
Heme–FMN 402 ± 2 244 ± 10 263 ± 8 –
Heme 380 ± 4 – – –
FMN–FeS – 251 ± 10 268 ± 10 N/d
FMN – 232 ± 9 284 ± 16 –
FeS – – – 214 ± 3
PDR [19] – 174 287 174
PDR (–FeS) [20] – 174 235 –
Intact P450 RhF data are from [12]. N/d indicates that this potential could not be determined, as its contribution to the absorbance changes on
reduction were masked by other prosthetic groups. PDR and PDR (–FeS) indicate the reduction potentials of the phthalate dioxygenase reductase,
and of its truncated form lacking FeS, for comparison [20,21].
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mately 240 mV (ox/sq) and 270 mV (sq/hq), with the
2Fe–2S potential at 214 mV. The P450 RhF FMN potentials
are essentially unaﬀected by the removal of the other domains
(Table 2). This contrasts with phthalate dioxygenase reductase,
where removal of the FeS moiety by trypsin digestion increases
the potential of the sq/hq couple to 235 mV [20,21].
Stopped-ﬂow kinetic experiments had already established
that intact P450 RhF displays a marked (500-fold) preference
for NADPH over NADH [12]. The nucleotide binding con-
stants for those constructs containing the FMN domain are
all very similar (NADPH Kd: 3.1–8.1 lM, NADH Kd: 2.2–
9.8 mM), demonstrating that separation of the domains does
not alter their nucleotide binding properties, and showing that
the approximately 500-fold preference for NADPH over
NADH observed for the intact P450 RhF is maintained.
This paper describes the ﬁrst domain dissection of the novel
class of P450s represented by P450 RhF. The properties of the
isolated domains of P450 RhF are little altered from those ob-
served in the intact enzyme. Each domain appears to operate
individually, with little dependence of kinetic and thermody-
namic properties on the presence or absence of its neighbours.
Expression of the FeS domain permits the ﬁrst characterisation
of its thermodynamic properties, since these are masked in the
intact enzyme by the intense spectral signals from heme and
FMN.
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